Management of bone metastases in patients with castration-resistant prostate cancer

Urologia Internationalis

Volumn 92, Issue 4, 2014, Pages 377-386

  Cathomas, Richard ^a   Bajory, Zoltan ^a   Bouzid, Mounira ^a   El Ghoneimy, Ahmed ^a   Gillessen, Silke ^a   Goncalves, Frederico ^a   Kacso, Gabriel ^a   Kramer, Gero ^a   Milecki, Piotr ^a   Pacik, Dalibor ^a   Tantawy, Wahid ^a   Lesniewski Kmak, Krzystof ^a  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

Bone metastases; Bone targeted therapy; Prostate cancer; Radiotherapy; Skeletal related events; Surgery

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY;

ARTHRALGIA; ASTHENIA; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CONJUNCTIVITIS; CONSENSUS; CRANIAL NERVE PARALYSIS; DRUG SAFETY; EPISCLERITIS; EYELID EDEMA; FATIGUE; FLU LIKE SYNDROME; FRACTURE; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MORBIDITY; NAUSEA; NEPHROTOXICITY; ORBIT INFLAMMATION; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPINAL CORD COMPRESSION; ACUTE PHASE RESPONSE; ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; EYE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; BONE; BONE NEOPLASMS; INTERDISCIPLINARY COMMUNICATION; MALE; METASTASIS; ONCOLOGY; PATHOLOGY; SECONDARY; STANDARDS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INTERDISCIPLINARY COMMUNICATION; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUALITY OF LIFE; SPINAL CORD COMPRESSION; TREATMENT OUTCOME;

EID: 84902543280     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000358258     Document Type: Review

References (87)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917
2. Townsend MF, Sanders WH, Northway RO, Graham SD Jr: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79: 545-550. (Pubitemid 27051780
3. Collinson MP, Tyrell CJ, Hutton C: Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif Tissue Int 1994; 54: 327-328. (Pubitemid 24097838
4. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA: The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16: 579-584. (Pubitemid 40613323
5. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755
6. Rigaud J, Tiguert R, Le Normand L, Karam G, Glemain P, Buzelin JM, Bouchot O: Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen Deprivation therapy. J Urol 2002; 168: 1423-1426. (Pubitemid 35034138
7. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202. (Pubitemid 18023133
8. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M; Zoledronic Acid Prostate Cancer Study Group: Long-Term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882. (Pubitemid 38807610
9. Halvorson KG, Sevcik MA, Ghilardi JR, Rosol TJ, Mantyh PW: Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. Clin J Pain 2006; 22: 587-600. (Pubitemid 44310159
10. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ: Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer 1983; 51: 918-924. (Pubitemid 13143171
11. Clarke NW, McClure J, George NJ: Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68: 74-80
12. Clarke NW, McClure J, George NJ: Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol 1992; 69: 64-70
13. Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, Kanis JA: Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987; 13: 41-49. (Pubitemid 17040425
14. Stenzl A: RANK ligand: A key role in cancerinduced bone destruction?. Eur Urol Suppl 2009; 8: 823-828
15. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 2003; 423: 337-342. (Pubitemid 40852708
16. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664
17. Mundy GR: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593
18. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003; 21: 1404-1411. (Pubitemid 46606423
19. US Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2007. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm071590.pdf (accessed February 25, 2011
20. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR: A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen crosslinked N-Telopeptides in urine. J Bone Miner Res 1992; 7: 1251-1258. (Pubitemid 23000964
21. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC: Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512. (Pubitemid 26128321
22. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925-4935. (Pubitemid 46223998
23. de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gomez-Caamano A, Ribal MJ, Vazquez F, Anido U, Samper P, Esteban E, Alvarez-Ossorio JL, Lara PC, San Jose LA, Contreras JA, del Alba AG, Gonzalez-Gragera B, Tabernero AJ, Gonzalez-Enguita C, Fernandez JM, Garcia-Escudero A, Gomez-Veiga F, Mendez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Manas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sanchez E, Unda M, Solsona E, Martinez-Javaloyas JM, Comet-Batlle J, Quicios C, Martin-Fernandez M, Mahillo-Fernandez I, Morote J: Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br J Cancer 2013; 108: 2565-2572
24. Ibrahim T, Farolfi A, Mercatali L, Ricci M, Amadori D: Metastatic bone disease in the era of bone-Targeted therapy: Clinical impact. Tumori 2013; 99: 1-9
25. Rybak LD, Rosenthal DI: Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med 2001; 45: 53-64. (Pubitemid 32586342
26. Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J, Krege S, Lehmann J, Rohde D, Schmidberger H, Uder M, Zeeb H; Association of Urologic Oncology of the German Cancer Society: Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: Recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int 2010; 85: 1-10
27. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Prostate Cancer, vol 1, 2011
28. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, van Der Kwast TH, Wiegel T, Zattoni F: Guidelines on Prostate Cancer. European Association of Urology 2013, update March 2013. http://www.uroweb.org/gls/pdf/09- Prostate-Cancer-LR.pdf. 29 Rosenthal DI: Radiologic diagnosis of bone metastases. Cancer 1997; 80(8 suppl):1595-1607
29. Schaffer DL, Pendergrass HP: Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 1976; 121: 431-434
30. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, van Poznak CH: NCCN task force report: Bone health in cancer care. J Natl Compr Canc Netw 2009; 7(suppl 3):S1-S32; quiz S33-S35
31. Yu HH, Tsai YY, Hoffe SE: Overview of diagnosis and management of metastatic disease to bone. Cancer Control 2012; 19: 84-91
32. Tombal B, Lecouvet F: Modern Detection of prostate cancer's bone metastasis: Is the bone scan era over?. Adv Urol 2012; 2012: 893193
33. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139
34. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology 2011. http://www.nccn.org/professionals/ physician-gls/f-guidelines. asp (accessed November 26, 2012
35. Saad F, Hotte SJ: Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J 2010; 4: 380-384
36. Heidenreich A, Witjes WP, Bjerklund-Johansen TE, Patel A; EAU Research Foundation: Therapies used in prostate cancer patients by European urologists: Data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates. Urol Int 2012; 89: 30-38
37. So A, Chin J, Fleshner N, Saad F: Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can Urol Assoc J 2012; 6: 465-470
38. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F; ESMO Guidelines Working Group: Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23(suppl 7):vii139-vii154
39. Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M: Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005; 97: 798-804. (Pubitemid 40909122
40. Foro Arnalot P, Fontanals AV, Galceran JC, Lynd F, Latiesas XS, de Dios NR, Castillejo AR, Bassols ML, Galan JL, Conejo IM, Lopez MA: Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol 2008; 89: 150-155
41. Sande TA, Ruenes R, Lund JA, Bruland OS, Hornslien K, Bremnes R, Kaasa S: Long-Term follow-up of cancer patients receiving radiotherapy for bone metastases: Results from a randomised multicentre trial. Radiother Oncol 2009; 91: 261-266
42. Dearnaley DP, Bayly RJ, A'Hern RP, Gadd J, Zivanovic MM, Lewington VJ: Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89?. Clin Oncol (R Coll Radiol) 1992; 4: 101-107
43. Salazar OM, Sandhu T, da Motta NW, Escutia MA, Lanzos-Gonzales E, Mouelle-Sone A, Moscol A, Zaharia M, Zaman S: Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: A randomized phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 2001; 50: 765-775. (Pubitemid 32519600
44. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, et al: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-813. (Pubitemid 23123384
45. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O; ALSYMPCA Investigators: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223
46. Bickels J, Kollender Y, Wittig JC, Meller I, Malawer MM: Function after resection of humeral metastases: Analysis of 59 consecutive patients. Clin Orthop Relat Res 2005; 437: 201-208. (Pubitemid 41099089
47. Harrington KD: Impending pathologic fractures from metastatic malignancy: Evaluation and management. Instr Course Lect 1986; 35: 357-381
48. Kollender Y, Bickels J, Price WM, Kellar KL, Chen J, Merimsky O, Meller I, Malawer MM: Metastatic renal cell carcinoma of bone: Indications and technique of surgical intervention. J Urol 2000; 164: 1505-1508
49. Ward WG, Holsenbeck S, Dorey FJ, Spang J, Howe D: Metastatic disease of the femur: Surgical treatment. Clin Orthop Relat Res 2003; 415(suppl):S230-S244. (Pubitemid 37323342
50. Rades D, Huttenlocher S, Dunst J, Bajrovic A, Karstens JH, Rudat V, Schild SE: Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol 2010; 28: 3597-3604
51. Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, Mohiuddin M, Young B: Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: A randomised trial. Lancet 2005; 366: 643-648. (Pubitemid 41176016
52. Klimo P Jr, Thompson CJ, Kestle JR, Schmidt MH: A meta-Analysis of surgery versus conventional radiotherapy for the treatment of metastatic spinal epidural disease. Neuro Oncol 2005; 7: 64-76. (Pubitemid 40310194
53. Bickels J, Dadia S, Lidar Z: Surgical management of metastatic bone disease. J Bone Joint Surg Am 2009; 91: 1503-1516
54. Sahgal A, Larson DA, Chang EL: Stereotactic body radiosurgery for spinal metastases: A critical review. Int J Radiat Oncol Biol Phys 2008; 71: 652-655
55. Chang EL, Shiu AS, Mendel E, Mathews LA, Mahajan A, Allen PK, Weinberg JS, Brown BW, Wang XS, Woo SY, Cleeland C, Maor MH, Rhines LD: Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 2007; 7: 151-160. (Pubitemid 47219748
56. Coleman RE, Rathbone E, Brown JE: Management of cancer treatment-induced bone loss. Nat Rev Rheumatol 2013; 9: 365-374
57. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468
58. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK; Mrc Pr05 Collaborators: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 95: 1300-1311. (Pubitemid 37160863
59. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21: 4277-4284. (Pubitemid 46621802
60. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-Term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009; 10: 872-876
61. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ: A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-1228. (Pubitemid 43342512
62. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011; 377: 813-822
63. Brown JE, Cleeland CS, Fallowfield LJ, Patrick DL, Fizazi K, Smith MR, Maroto JP, Michel MS, Feng A, Goessl C, Chung K: Pain outcomes in patients with bone metastases from castrate-resistant prostate cancer: Results from a phase 3 trial of denosumab vs. zoledronic acid. Eur Urol 2011; 10(2 suppl): 336
64. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C: Denosumab and bone-metastasisfree survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46
65. Bock O, Boerst H, Thomasius FE, Degner C, Stephan-Oelkers M, Valentine SM, Felsenberg D: Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 2007; 7: 144-148. (Pubitemid 47249003
66. Maxwell C, Swift R, Goode M, Doane L, Rogers M: Advances in supportive care of patients with cancer and bone metastases: Nursing implications of zoledronic acid. Clin J Oncol Nurs 2003; 7: 403-408
67. Olson K, van Poznak C: Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007; 13: 223-229
68. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V: The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41: 326-331
69. Gallacher SJ, Ralston SH, Patel U, Boyle IT: Side-effects of pamidronate. Lancet 1989; 2: 42-43. (Pubitemid 19158178
70. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ: Long-Term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744. (Pubitemid 37238631
71. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J: Long-Term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-2621. (Pubitemid 38715767
72. Stopeck A, Fallowfield L, Patrick D, Cleeland CS, De Boer RH, Steger GG, Qian Y, Jiang Q, Dansey RD, Chung K: Effects of denosumab versus zoledronic acid (ZA) on pain in patients (pts) with metastatic breast cancer: Results from a phase III clinical trial (abstract). J Clin Oncol 2010; 28(suppl 15):A1024
73. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132
74. Skugor M: Hypocalcemia. Cleveland, The Cleveland Clinic Foundation, 2004. http:// www.clevelandclinicmeded.com/medicalpubs/ diseasemanagement/ endocrinology/ hypocalcemia/.
75. European Medicines Agency: Assessment Report for XGEVA. European Medicines Agency, 2011. http://www.ema.europa.eu/ docs/en-GB/document-library/ EPAR-Public-assessment-report/human/002173/WC500110384.pdf
76. Hadji P, Aapro M, Costa L, Gnant M: Antiresorptive treatment options and bone health in cancer patients - safety profiles and clinical considerations. Cancer Treat Rev 2012; 38: 815-824
77. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-1571
78. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S: Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875-4882
79. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S: Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25: 4431-4437. (Pubitemid 350013849
80. Estilo CL, van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM: Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008; 13: 911-920
81. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826-836. (Pubitemid 351768801
82. Migliorati CA, Siegel MA, Elting LS: Bisphosphonate-Associated osteonecrosis: A long-Term complication of bisphosphonate treatment. Lancet Oncol 2006; 7: 508-514. (Pubitemid 43779167
83. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, Altmeyer A, Csermak-Renner K, McGrath L, Lantwicki L, Hohneker JA: Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006. Crit Rev Oncol Hematol 2007; 62: 148-152. (Pubitemid 46575276
84. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005; 23: 8580-8587. (Pubitemid 46211499
85. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T: Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006; 24: 945-952. (Pubitemid 46638849
86. Lipton A: The safety of zoledronic acid. Expert Opin Drug Saf 2007; 6: 305-313
87. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012; 48: 3082-3092.